Zaviye · Coverage map
Merck and Moderna melanoma vaccine shows positive trial results
South China Morning Post
Merck and Moderna announced encouraging results from a late-stage trial of their personalized mRNA cancer vaccine, significantly reducing melanoma recurrence.
17 sources across Turkish, Spanish, fr, English · blind spot: little coverage from the right
Left 29% · Center 59% · Right 12%
How outlets framed it
All sources: Merck and Moderna have announced positive results from a late-stage trial of their personalized mRNA cancer vaccine for melanoma, which significantly reduced the recurrence of the disease.
Key divergence: While most sources report the trial success and its implications for melanoma treatment, Hindustan Times and AP News specifically note the substantial surge in Moderna's stock price following the announcement.
Source-by-source bias tags and translations live in the interactive view.
Reported by
Aa En · Apnews · Arstechnica · Axios · Bbc Turkce · Bloomberg · Cnn · Cumhuriyet · Hindustantimes · Liberation · Publico Es · Reuters · Scmp · Thenational